|
Market Closed -
Nasdaq
21:00:00 06/10/2026 BST
|
5-day change | 1st Jan Change | ||
| 174.86 USD | -7.73% |
|
-10.13% | +6.71% |
| 10-06 | Repligen Insider Sold Shares Worth $1,036,654, According to a Recent SEC Filing | MT |
| 10-06 | Repligen Closes BioLife Solutions Acquisition | MT |
Company Valuation: Repligen Corporation
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 14,643 | 9,401 | 10,039 | 8,064 | 9,224 | 9,868 | - | - |
| Change | - | -35.8% | 6.78% | -19.67% | 14.38% | 6.99% | - | - |
| Enterprise Value (EV) 1 | 14,405 | 9,062 | 9,357 | 7,833 | 9,200 | 9,603 | 9,430 | 9,206 |
| Change | - | -37.09% | 3.26% | -16.29% | 17.46% | 4.39% | -1.8% | -2.37% |
| P/E | 118x | 52.3x | 243x | -313x | 191x | 232x | 101x | 72.1x |
| PBR | 8.67x | 4.92x | 5.09x | 4.09x | 4.38x | 4.52x | 4.21x | 3.82x |
| PEG | - | 1.2x | -3.1x | 2x | -1x | -19x | 1x | 1.8x |
| Capitalization / Revenue | 21.8x | 11.7x | 15.7x | 12.7x | 12.5x | 11.9x | 10.1x | 8.56x |
| EV / Revenue | 21.5x | 11.3x | 14.6x | 12.3x | 12.5x | 11.6x | 9.66x | 7.99x |
| EV / EBITDA | 62.5x | 36.7x | 73.1x | 66.8x | 65.6x | 56.4x | 42.9x | 32.6x |
| EV / EBIT | 66.9x | 39x | 99.2x | 95.4x | 90.4x | 73.5x | 53.2x | 37.8x |
| EV / FCF | 277x | 104x | 120x | 52.3x | 98x | 79.6x | 63.1x | 46.2x |
| FCF Yield | 0.36% | 0.96% | 0.83% | 1.91% | 1.02% | 1.26% | 1.59% | 2.16% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 2.24 | 3.24 | 0.74 | -0.46 | 0.86 | 0.755 | 1.725 | 2.424 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 670.5 | 801.5 | 638.8 | 634.4 | 738.3 | 827 | 976.1 | 1,152 |
| EBITDA 1 | 230.5 | 246.9 | 128 | 117.3 | 140.3 | 170.1 | 220 | 282.7 |
| EBIT 1 | 215.2 | 232.2 | 94.29 | 82.08 | 101.8 | 130.7 | 177.4 | 243.6 |
| Net income 1 | 128.3 | 186 | 41.58 | -25.51 | 48.89 | 41.81 | 98.69 | 140.9 |
| Net Debt 1 | -237.8 | -339.1 | -681.9 | -231.8 | -23.81 | -264.9 | -438 | -662 |
| Reference price 2 | 264.84 | 169.31 | 179.80 | 143.94 | 163.86 | 174.86 | 174.86 | 174.86 |
| Nbr of stocks (in thousands) | 55,289 | 55,524 | 55,832 | 56,027 | 56,291 | 56,436 | - | - |
| Announcement Date | 17/02/22 | 22/02/23 | 21/02/24 | 20/02/25 | 24/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 251x | 12.61x | 61.07x | -.--% | 9.87B | |
| 29.3x | 3.93x | 15.19x | 2.57% | 170B | |
| 18.81x | 3.43x | 12.27x | 3.2% | 111B | |
| 22.18x | 4.35x | 15.2x | 1.26% | 107B | |
| 25.57x | 2.52x | 10.12x | 2.8% | 75.95B | |
| 17.32x | 0.2x | 12.68x | 0.75% | 60.37B | |
| 30x | 7.4x | 19.18x | 1.33% | 53.53B | |
| 34.82x | 3.38x | 11.57x | 2.17% | 49.11B | |
| 35.69x | 8.87x | 24.95x | -.--% | 40.6B | |
| 34.92x | 6.12x | 19.22x | -.--% | 31.47B | |
| Average | 49.96x | 5.28x | 20.15x | 1.41% | 70.89B | |
| Weighted average by Cap. | 29.30x | 4.17x | 15.40x | 1.92% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- RGEN Stock
- Valuation Repligen Corporation
Select your edition
All financial news and data tailored to specific country editions
